PDS Biotechnology Corp — Director's Dealing 2017

Mar 13, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Edge Therapeutics, Inc. (EDGE)
CIK: 0001472091
Period of Report: 2017-03-01

Reporting Person: Einhorn Andrew J. (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-03-01	Common Stock	X	1567	$2.39	Acquired	43223	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-03-01	Warrants (right To Purchase)	$2.39	X	1567	Disposed	2017-09-09	Common Stock (1567)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	83592	Indirect

Footnotes

F1: The Reporting Person is the sole managing member of Harpua, LLC and may be deemed to beneficially own these shares. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.